Mark Pritchard

Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS)

This document represents the first position statement produced by the British Society of Gastroenterology and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, setting out the minimum expected standards in diagnostic upper gastrointestinal endoscopy. The need for this statement has arisen from the recognition that while technical competence can be rapidly acquired, in practice the performance of a high-quality examination is variable, with an unacceptably high rate of failure to diagnose cancer at endoscopy. The importance of detecting early neoplasia has taken on greater significance in this era of minimally invasive, organ-preserving endoscopic therapy. In this position statement we describe 38 recommendations to improve diagnostic endoscopy quality. Our goal is to emphasise practices that encourage mucosal inspection and lesion recognition, with the aim of optimising the early diagnosis of upper gastrointestinal disease and improving patient outcomes.

Changing Trends in Peptic Ulcer Disease: The Rise of NSAID-Induced and Fall of Helicobacter pylori-Induced Ulcers

Introduction Non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori are the main causes of peptic ulcer disease (PUD). Data from the UK from 1997 to 2005 indicated that the aetiology is slowly changing as the prevalence of H pylori and use of non-aspirin NSAIDs (NANSAIDs) has been decreasing while the use of low-dose aspirin (LDA; ≤325 mg/day) has been increasing. Methods In order to investigate these changing trends, subjects who presented with endoscopically confirmed PUD at Royal Liverpool Hospital between July 2005 and June 2010 were identified from the endoscopy database and recruited either prospectively or retrospectively. Recruits were interviewed using a structured questionnaire and GPs were contacted to capture data missing from case-notes. Patients were categorised as either NSAID users (those on NSAIDs within 2 weeks) or non-users (those not on NSAIDs within 3 months of endoscopy). Upper GI bleeding (UGIB) was defined as haematemesis, melaena or anaemia (haemoglobin drop ≤2g/dl) and/or endoscopic stigmata of recent bleeding. H pylori status was determined by the rapid urease test and/or histology, or serology (IgG, ELISA) where these were negative or not done. Results Of the 389 patients enrolled, 220 (57%) were using NSAIDs and 169 (43%) were non-users. 29% of the whole cohort were taking LDA alone. 57% of the patients were 65 years or above, comprising 66% of NSAID users and 41% of non-users, with mean ages of 67 and 60 (SD 13.5 vs16) years, respectively. The mean age of those using LDA alone was 70 (SD 10.6) years. H pylori was positive in 41% of ulcers (46% DU, 33% GU). Amongst NSAID users, 51% were on LDA, 30% on NANSAIDS, 15% on both LDA and NANSAIDs and 4% on high dose aspirin. NSAID users had more GU (59% vs. 45%, p=0.006), fewer DU (31% vs 48%, p=0.001) and were less likely to be H pylori positive (34% vs. 49%, p=0.005); there was no difference in gender (% males 50 vs. 56, p=0.318) or prevalence of UGIB (22% vs 20%, p=0.697) between the two groups. Compared to NANSAID users, LDA users were more likely to be H pylori positive (43% vs. 23%, p=0.003) with a similar prevalence of UGIB (21% vs. 20%, p=0.987). 22% of patients with PUD were neither using NSAIDs nor H pylori positive. Conclusion NSAIDs, particularly LDA, were the commonest cause of PUD in this cohort, especially in those over 65 years. Our findings are compatible with the steady decline in the prevalence of H pylori -positive PUD and increase in non-NSAID non- H pylori PUD over recent years. LDA users were older and more likely to be H pylori positive compared to those using NANSAIDs; the significance of this in terms of ulcer pathogenesis needs further study.